Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
19
PHBBF Quote, Financials, Valuation and Earnings
Last price:
$1.93
Seasonality move
:
0%
Day range:
$1.93 - $1.93
52-week range:
$1.93 - $1.93
Dividend yield:
1.44%
P/E ratio:
16.26x
P/S ratio:
1.83x
P/B ratio:
1.67x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$3.4B
Revenue:
$1.7B
EPS (TTM):
$0.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing Co., Ltd.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.92% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing Co., Ltd.
|
$1.93 | -- | $3.4B | 16.26x | $0.03 | 1.44% | 1.83x |
|
ADAG
Adagene, Inc.
|
$1.91 | $9.22 | $90.2M | -- | $0.00 | 0% | 861.40x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.86 | $4.00 | $17.6M | -- | $0.00 | 0% | 0.50x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.75 | -- | $5.7M | -- | $0.00 | 0% | 1.41x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.70 | $49.49 | $2.1B | -- | $0.00 | 0% | 4.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing Co., Ltd.
|
30.42% | 0.012 | 25.56% | 1.01x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing Co., Ltd.
|
$168.7M | $71.9M | 6.8% | 9.62% | 14.35% | $41.1M |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Pharmaron Beijing Co., Ltd. vs. Competitors
-
Which has Higher Returns PHBBF or ADAG?
Adagene, Inc. has a net margin of 11.52% compared to Pharmaron Beijing Co., Ltd.'s net margin of --. Pharmaron Beijing Co., Ltd.'s return on equity of 9.62% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing Co., Ltd.33.65% $0.03 $3B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About PHBBF or ADAG?
Pharmaron Beijing Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 381.94%. Given that Adagene, Inc. has higher upside potential than Pharmaron Beijing Co., Ltd., analysts believe Adagene, Inc. is more attractive than Pharmaron Beijing Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing Co., Ltd.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is PHBBF or ADAG More Risky?
Pharmaron Beijing Co., Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHBBF or ADAG?
Pharmaron Beijing Co., Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 1.44%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing Co., Ltd. pays 18.21% of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend. Pharmaron Beijing Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHBBF or ADAG?
Pharmaron Beijing Co., Ltd. quarterly revenues are $501.3M, which are larger than Adagene, Inc. quarterly revenues of --. Pharmaron Beijing Co., Ltd.'s net income of $57.7M is higher than Adagene, Inc.'s net income of --. Notably, Pharmaron Beijing Co., Ltd.'s price-to-earnings ratio is 16.26x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing Co., Ltd. is 1.83x versus 861.40x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing Co., Ltd.1.83x 16.26x $501.3M $57.7M ADAGAdagene, Inc.861.40x -- -- --
-
Which has Higher Returns PHBBF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of 11.52% compared to Pharmaron Beijing Co., Ltd.'s net margin of -353.92%. Pharmaron Beijing Co., Ltd.'s return on equity of 9.62% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing Co., Ltd.33.65% $0.03 $3B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About PHBBF or CASI?
Pharmaron Beijing Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 366.8%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Pharmaron Beijing Co., Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Pharmaron Beijing Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing Co., Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.0 0 0 -
Is PHBBF or CASI More Risky?
Pharmaron Beijing Co., Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock PHBBF or CASI?
Pharmaron Beijing Co., Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 1.44%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing Co., Ltd. pays 18.21% of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Pharmaron Beijing Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHBBF or CASI?
Pharmaron Beijing Co., Ltd. quarterly revenues are $501.3M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Pharmaron Beijing Co., Ltd.'s net income of $57.7M is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Pharmaron Beijing Co., Ltd.'s price-to-earnings ratio is 16.26x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing Co., Ltd. is 1.83x versus 0.50x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing Co., Ltd.1.83x 16.26x $501.3M $57.7M CASICASI Pharmaceuticals, Inc.0.50x -- $3.1M -$10.9M
-
Which has Higher Returns PHBBF or CPHI?
China Pharma Holdings, Inc. has a net margin of 11.52% compared to Pharmaron Beijing Co., Ltd.'s net margin of -86.16%. Pharmaron Beijing Co., Ltd.'s return on equity of 9.62% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing Co., Ltd.33.65% $0.03 $3B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About PHBBF or CPHI?
Pharmaron Beijing Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing Co., Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Pharmaron Beijing Co., Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing Co., Ltd.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is PHBBF or CPHI More Risky?
Pharmaron Beijing Co., Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock PHBBF or CPHI?
Pharmaron Beijing Co., Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 1.44%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing Co., Ltd. pays 18.21% of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend. Pharmaron Beijing Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHBBF or CPHI?
Pharmaron Beijing Co., Ltd. quarterly revenues are $501.3M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Pharmaron Beijing Co., Ltd.'s net income of $57.7M is higher than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Pharmaron Beijing Co., Ltd.'s price-to-earnings ratio is 16.26x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing Co., Ltd. is 1.83x versus 1.41x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing Co., Ltd.1.83x 16.26x $501.3M $57.7M CPHIChina Pharma Holdings, Inc.1.41x -- $756.2K -$651.5K
-
Which has Higher Returns PHBBF or SVA?
Sinovac Biotech Ltd. has a net margin of 11.52% compared to Pharmaron Beijing Co., Ltd.'s net margin of --. Pharmaron Beijing Co., Ltd.'s return on equity of 9.62% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing Co., Ltd.33.65% $0.03 $3B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About PHBBF or SVA?
Pharmaron Beijing Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing Co., Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Pharmaron Beijing Co., Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing Co., Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is PHBBF or SVA More Risky?
Pharmaron Beijing Co., Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock PHBBF or SVA?
Pharmaron Beijing Co., Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 1.44%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Pharmaron Beijing Co., Ltd. pays 18.21% of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend. Pharmaron Beijing Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHBBF or SVA?
Pharmaron Beijing Co., Ltd. quarterly revenues are $501.3M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. Pharmaron Beijing Co., Ltd.'s net income of $57.7M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, Pharmaron Beijing Co., Ltd.'s price-to-earnings ratio is 16.26x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing Co., Ltd. is 1.83x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing Co., Ltd.1.83x 16.26x $501.3M $57.7M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns PHBBF or ZLAB?
Zai Lab Ltd. has a net margin of 11.52% compared to Pharmaron Beijing Co., Ltd.'s net margin of -30.98%. Pharmaron Beijing Co., Ltd.'s return on equity of 9.62% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing Co., Ltd.33.65% $0.03 $3B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About PHBBF or ZLAB?
Pharmaron Beijing Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 164.64%. Given that Zai Lab Ltd. has higher upside potential than Pharmaron Beijing Co., Ltd., analysts believe Zai Lab Ltd. is more attractive than Pharmaron Beijing Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing Co., Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is PHBBF or ZLAB More Risky?
Pharmaron Beijing Co., Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock PHBBF or ZLAB?
Pharmaron Beijing Co., Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 1.44%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing Co., Ltd. pays 18.21% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. Pharmaron Beijing Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHBBF or ZLAB?
Pharmaron Beijing Co., Ltd. quarterly revenues are $501.3M, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. Pharmaron Beijing Co., Ltd.'s net income of $57.7M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, Pharmaron Beijing Co., Ltd.'s price-to-earnings ratio is 16.26x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing Co., Ltd. is 1.83x versus 4.54x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing Co., Ltd.1.83x 16.26x $501.3M $57.7M ZLABZai Lab Ltd.4.54x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
50
PLAB alert for Dec 10
Photronics, Inc. [PLAB] is up 45.35% over the past day.
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
